Glial tumors with oligodendroglial components are considered chemo-responsive. Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m 2 on days 1 -5 every 4 weeks for 6 cycles). The primary endpoint was 6-month progression-free survival (PFS) with response rate (RR), median PFS, and median overall survival (OS) as secondary endpoints. Of 39 evaluable patients at the 6-month time point (median follow-up, 34 months), 6-month PFS was 77% (95% confidence interval [CI], 74.5% -79.3%). There were 15 complete responses (CRs, 38%), 6 partial responses (PRs, 15%), and 9 disease stabilization (23%). The median PFS was 21 months (95% CI, 3-39 months), and the median OS was 43 months (95% CI, 20 -66 months). Chromosome 1p/19q codeletions were seen in 47% (18 of 38) of the patients, and O-6-methylguanine-DNA-methyltransferase (MGMT) methylation was seen in 48% (10 of 21) of the patients. All patients with OD showed MGMT methylation and most (71%) had chromosome 1p/19q codeletions. Conversely, fewer patients with OA showed MGMT methylation (23%) or had chromosome 1p/19q codeletions (31%). The presence of either 1p/19q codeletion or MGMT methylation was associated with increased RR at 6 months but not with improved PFS or OS. Only 18% of the patients (7 of 40) experienced treatment-related grade 3/4 toxicities. This regimen was active and well tolerated. These data add to the growing body of data showing that primary chemotherapy may be an acceptable alternative to radiotherapy for patients with gliomas containing oligodendroglial histology.
P rimary cerebral tumors are responsible for 2% of all cancer deaths, with about 13 000 persons dying each year in the USA. 1 The largest subgroup of these tumors are high-grade astrocytomas such as glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA). 2 Up to 25% of gliomas contain oligodendroglial histology, 2, 3 and these have a better prognosis than pure astrocytomas. 3, 4 The identification of oligodendroglial components can be challenging and ideally requires an experienced neuropathologist. 5 In the setting of recurrent anaplastic oligodendrogliomas (OD) or oligoastrocytomas (OA), treatment with alkylating agents such as procarbazine, lomustine, and vincristine (PCV) or temozolomide has been efficacious and tolerable. 3 Increasingly, chemotherapy is being incorporated into the initial treatment of patients with newly diagnosed OD/OA. Conventional treatment is diagnostic or debulking surgery followed by radiotherapy. The value of radiotherapy in this setting is not based on randomized data. 3 Two large prospective trials have shown only modest benefits from the addition of adjuvant PCV chemotherapy to radiotherapy for these patients. 6, 7 One study administered PCV before radiotherapy 7 and one administered PCV after radiotherapy. 6 Although chemotherapy increased progression-free survival (PFS), there was no increase in overall survival (OS). This was partly attributed to the extensive (80%) use of salvage chemotherapy in patients who progressed on radiotherapy. Instead of concurrent chemo-radiation, other trials are exploring whether initial treatment with chemotherapy alone is feasible and safe in these patients. 4, 8, 9 The preliminary results of one large study (NOA-04) 4 suggest that this is the case. Patients with AA/OD/OA were randomized to initial treatment with radiotherapy or chemotherapy (PCV or temozolomide), with crossover at the time of progression. Outcomes were identical whether the initial treatment was radiotherapy or chemotherapy (PFS was 31 and 32 months, respectively; OS was .60 months in both arms). This was true whether the initial chemotherapy was PCV or temozolomide, although temozolomide was much better tolerated. Another important trial which will address this question is the on-going EORTC 26081 Phase III trial of radiotherapy, temozolomide, or combined modality therapy in patients with newly diagnosed OD/OA with 1p/19q codeletions (http://www.eortc.be/ protoc/details.asp?protocol=26081).
Chromosome 1p/19q codeletion is one of a number of biomarkers that are recognized in patients with OD/OA. It is found in 25%-75% of tumors. 6 -10 The presence of chromosome 1p/19q codeletions is more common in OD than in OA (57% vs 14%, respectively, in one study). 7 It is associated with increased chemo-responsiveness and increased PFS after adjuvant PCV treatment. 3, 4, 6, 7 Studies using temozolomide have also found that the presence of chromosome 1p/19q codeletions is a favorable predictive biomarker. 8, 11, 12 The mechanisms underlying these observations are not understood. 3 Another biomarker in OD/OA is O-6-methylguanine-DNAmethyltransferase (MGMT). MGMT promoter methylation results in the silencing of this gene, with subsequent inhibition of DNA repair mechanisms that would otherwise neutralize the cytotoxic effects of alkylating agents. 13 At least in GBM, it appears to be predictive of response to temozolomide-based treatment. 13, 14 In OD/ OA, data suggest that MGMT promoter methylation occurs in 55%-80% of cases, 9 -11,15,16 is correlated with the presence of chromosome 1p/19q codeletions, 9 -11,15,16 and may be predictive of response to both radiotherapy and chemotherapy. 4 We now describe a Phase II study of temozolomide (200 mg/m 2 on days 1 -5 every 28 days) as the primary therapy for patients with OD/OA, with correlative studies to assess chromosome 1p/19q codeletions and MGMT promoter methylation. Temozolomide was chosen as it is better tolerated than PCV, without progressive myelosuppression and neuropathy.
Patients and Methods

Patients Characteristics
Patients with histologically confirmed anaplastic OD/ OA who had not previously been treated with radiotherapy or chemotherapy were recruited into this multicenter study between July 2003 and December 2006. The Human Research and Ethics Committees of each hospital approved the trial and written informed consent was obtained from all patients. Eligible patients were required to be at least 18 years of age and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Prior debulking surgery was allowed. Adequate laboratory values were required, including a hemoglobin !10 g/dL; an absolute neutrophil count !1500/mL; a platelet count !100 000/mL; aspartate aminotransferase and alanine aminotransferase ,3Â the upper limit of laboratory normal (ULN); and creatinine and serum bilirubin ,1.5Â ULN. Patients on corticosteroids had to be on a stable or reducing dose for 1 week prior to study entry. Patients were excluded if they were pregnant or breast-feeding, had not recovered fully from surgery, had been treated with any chemotherapy or radiotherapy, or had a severe intercurrent illness.
Study Design
This study was an open-label, multicenter, Phase II study. The histologic criteria used to diagnose OD and OA were based on the WHO classification of central nervous system tumors. 17 All patients were staged with a baseline magnetic resonance imaging (MRI) scan in the 21 days prior to commencing temozolomide. Patients who underwent tumor resection were staged with an MRI within 3 days of surgery if possible. MRI scans were performed after every 2 cycles or if clinically indicated. An MRI was also performed at the end of the study (day 28 of cycle 6 of temozolomide). Response was assessed using the MacDonald criteria. 18 Patients with macroscopic complete resections were classed as complete responders if there was no tumor progression at 6 months. Tumor sections were sent for a centralized pathology review by a single experienced neuropathologist (R.K.) at the Austin Hospital, Melbourne, Australia. Blood and tumor specimens for DNA analysis were sent to a reference laboratory (The Molecular Oncology Laboratory, Royal Children's Hospital, Melbourne, Australia) and were scored by a single person (E.A.).
Treatment
Temozolomide was administered at an initial dose of 200 mg/m 2 on days 1-5. Treatment was repeated every 28 days for a total of 6 cycles. Prophylactic hematopoietic growth factors were not used routinely but were allowed for secondary prophylaxis after febrile neutropenia. Following chemotherapy, patients could undergo consolidation radiation therapy at the treating clinician's discretion. Dose modifications were based on the National Cancer Institute Common Toxicity Criteria (Version 3). Subsequent cycles were delayed until the neutrophil count was .1500 cells/mL, platelets .100 000/mL, hemoglobin .10 g/dL, liver function tests 2.5Â ULN, creatinine ,1.5Â ULN, total bilirubin within normal limits, and all other toxicities resolved to baseline or grade 1. For hematological toxicity, the dose of temozolomide was reduced to 150 mg/m 2 for grade 3 thrombocytopenia or neutropenia and to 100 mg/m 2 for grade 4 thrombocytopenia or neutropenia. For patients experiencing drug-related nonhematological toxicity, those with grade 3 toxicity had their dose reduced by 25% and those with grade 4 toxicity were withdrawn from the study.
Sample Processing
Mononuclear cells were isolated from whole blood after red cell lysis and stored at 280 8 C. DNA of suitable concentration and quality was recovered from all blood samples. DNA was extracted from formalin-fixed paraffin embedded tumor sections using the Dneasy kit (Qiagen). Recovered DNA was of variable concentration. DNA was stored at 280 8 C prior to analysis for loss of heterozygosity (LOH) and MGMT promoter methylation.
Analysis for LOH at Chromosomes 1p and 19q
Paired blood and tumor DNA samples (50 -100 ng/mL) were examined for LOH using microsatellite markers mapping to chromosome 1p (D1S2734, D1S199, and D1S169) and chromosome 19q (D19S219, D19S393, D19S220, and D19S596). Primers were labeled with Fam, Hex, or Tet and pooled microsatellite PCRs were electrophoresed on 4.5% 0.2 mm denaturing polyacrylamide gels on an ABI 377 DNA sequencer employing TAMRA 500 (Red) size standard. Sample lanes were tracked with Genescan software, Version 3.1.2, and analyzed using Genotyper, Version 2.1, at the Australian Genome Research Facility (AGRF). Paired samples were scored blind by one investigator (E.A.) and tabulated. Samples were scored as having allele loss on either chromosome 1p or chromosome 19q if at least one marker in the panel had evidence of LOH. LOH was either partial (mosaic) or complete, reflecting the heterogeneity of the cell population within the tumor section. Samples with mosaic LOH were scored as LOH-positive. Samples maintaining heterozygosity and uninformative samples were grouped as no LOH.
Analysis for MGMT Promoter Methylation Status
Tumor DNA samples were bisulfite modified using the Methyl Easy TM Kit (Human Genetic Signatures). Two methods were used to examine MGMT promoter methylation. The first assay was from the Sequenom Standard Epipanel and examined CpG methylation in 8 CpG units (a total of 20 CpG sites) in the amplicon MGMT-002. The region analyzed is upstream of exon 1 and is within a large CpG island. The amplicon extended from the position 131 155 066 to 131 155 394 on chromosome 10. Amplicons were treated and run on MALDI-TOF mass spectrometry according to the manufacturer's (Sequenom) instructions. Tumors were scored as methylated where the peak ratios (methylated:unmethylated) of CpG units were .2 SD above the mean methylation peak ratio derived from 4 normal control peripheral blood DNA samples. The second assay utilized the technique of methylation-sensitive high-resolution melting (MS-HRM). 19 The region analyzed was 3 0 with respect to the Sequenom assay region and included the 5 0 region of MGMT exon 1 extending from 131 155 459 to 131 155 568. The amplicon analyzed was 109 bases in length and lies within the same CpG island analyzed in the Sequenom MGMT assay. Methylation was quantified relative to a series of standards prepared from fully methylated human DNA (Chemicon). Samples were arbitrarily scored as methylated where !4 of the 8 CpG units were methylated according to Sequenom analysis, or where the methylation score by MS-HRM was !10% (ie, .10% of the DNA present in the tumor section was methylated at the MGMT promoter). Samples were scored as unmethylated where 1 CpG unit was methylated by Sequenom analysis and/or where the methylation score by MS-HRM was 1%. Samples were scored as discrepant where !4 CpG units were methylated by Sequenom analysis and where the MS-HRM methylation score was 1%.
Statistical Analysis
The primary endpoint was PFS 6 months after commencing temozolomide treatment. Other endpoints were median PFS, response rates (RRs), and median OS. Time to progression was defined as the time from the start of study drug to the first evidence of progression. OS was defined as the time from the start of the study drug to death from any cause. A pragmatic sample of 50 patients were deemed feasible within the time frame and the resources available, and sufficient to assess the study endpoints and complete the planned correlative studies. However, the study was closed after 40 patients because of slowing accrual at the participating centers, predominantly related to a shift toward combined chemo-radiotherapy for high-grade gliomas after the publication of the EORTC/NCIC study. 20 All analysis was done using SPPS Version 16 and all P values are two-sided unless otherwise indicated. OS and PFS were estimated using the Kaplan -Meier curves and comparisons between groups were performed using the log-rank test. All evaluable patients were included in the analysis of OS and PFS except for 1 patient who was lost to follow-up after study withdrawal for toxicity post cycle 1 of treatment. For patients who progressed on treatment and required salvage treatment, PFS was censored at that time, whereas OS was censored at the time of last follow-up if death had not occurred at the time of study analysis. For all other patients, including those who had received consolidation radiotherapy, patients were censored at the time of last follow-up in the event that they had not progressed (for PFS) or died (for OS) at the time of analysis. Differences in RR based on dichotomous variables such as chromosomal status or tumor histology were analyzed by x 2 analysis or Fisher's exact test. 
Results
Treatment Delivery and Toxicity
The patient demographics are listed in Table 1 . Most patients (90%) were treated at the time of diagnosis (median time between diagnosis and study treatment of 23 days). Only 4 patients were treated .3 months after study diagnosis. At a median follow-up of 34 months (range 12 -53), all patients were evaluable for toxicity, and 39 patients were evaluable for efficacy (1 was lost to follow-up). A total of 216 temozolomide cycles were administered. The mean number of temozolomide cycles per patient was 5.4 (range 1-6). The mean dose of temozolomide was 1719 mg/cycle (range 800 -2500). Treatment with temozolomide was very well tolerated. A total of 37 grade 3/4 adverse events were reported in 15 patients (38% of the patients), of which 14 events were deemed unrelated to treatment. Many of the unrelated adverse events were neurological in nature: seizures/status epilepticus (4 patients), headache (3 patients), hydrocephalus (1 patient), ataxia (1 patient), cerebrospinal fluid leak (1 patient), and intratumoral hemorrhage (1 patient). Twenty-three grade 3/4 toxicities in 7 patients (18% of the patient) were attributed to temozolomide and are listed in Table 2 . Two patients (5%) discontinued treatment after 1 cycle of treatment for toxicity. A total of 8 cycles (4% of cycles) were dose-reduced (6 cases of myelosuppression, 1 case of myelosuppression with febrile neutropenia, and 1 case where the dose was recalculated because of a significant change in patient weight) in 7 patients. All of these dose reductions occurred in cycles 2 or 3 of treatment, and all of these patients subsequently went on to complete a total of 6 cycles of treatment. A total of 25 cycles (12% of cycles) were dose-delayed (16 cases for myelosuppression, 2 episodes for grade 2 infections, 1 case at investigator's discretion, 1 case at patient request, and 5 for miscellaneous reasons).
Treatment Efficacy
One patient was not evaluable for RR (CR or PR) at 6 months because the patient was lost to follow-up after withdrawing from the study because of grade 4 myelosuppression in cycle 1. Of the remaining 39 patients, the 6-month PFS rate was 77% (95% confidence interval [CI], 74.5% -79.3%). The median PFS was 21 months (95% CI, 3-39 months), and the median OS was 43 months (95% CI, 20 -66 months). There were 15 CR (38%), 6 PR (15%), 9 disease stabilizations (23%), and 9 disease progressions (23%). Of the 9 patients who progressed during temozolomide therapy, salvage treatment was with radiotherapy (6 patients), surgery followed by chemo-radiation (1 patient), chemoradiation alone (1 patient), or surgery alone (1 patient). Of the 30 remaining patients who did not progress during temozolomide treatment, 9 patients received consolidation radiotherapy at the end of temozolomide treatment (median dose 59.4 Gy, range 54 -60). Prior to these 9 patients starting radiotherapy, 5 patients had disease stabilization, 3 patients had PRs, and 1 patient had a CR. As it is possible that the use of consolidation radiotherapy might impact the determination of OS and PFS, an unplanned exploratory analysis excluding these 9 patients found that the median OS (53 months) and the median PFS (not yet reached) in the 21 patients who only received temozolomide treatment was at least as good as that of the whole study population. Although small numbers preclude a definitive analysis, the increased responsiveness to temozolomide appeared to hold true in a preplanned subset analysis comparing patients with OD or OA (Table 3) . Neither the presence nor the absence of 1p/19q codeletion affected PFS or OS (Fig. 1) . Determination of MGMT promoter methylation status was not possible in just under half of the patients-13 patients had inadequate recovery following bisulfite modification of the tumor, and 6 patients had discrepant results between the two methods of analysis. This rate of missing results is similar to that reported in other studies. 4, 9, 10, 14 Of the remaining 21 patients, 10 patients (48%) showed MGMT promoter methylation using both analysis methods. Patients with MGMT promoter methylation also showed a substantial trend toward increased objective tumor response compared with those lacking MGMT methylation (70% vs 27%, P ¼ .086). This was maintained in subset analysis based on tumor histology (Table 4) . Neither the presence nor the absence of MGMT promoter methylation affected OS or PFS (Fig. 1) .
Twenty patients had results for both chromosome 1p/19q codeletion and MGMT promoter methylation analysis. Of these 20 patients, patients with chromosome 1p/19q codeletions were significantly more likely to show MGMT promoter methylation compared with those who lacked chromosome 1p/ 19q codeletions (Table 5 ; 89% vs 18%, P ¼ .005). In a subset analysis based on the tumor histology of these 20 patients, all patients with OD showed MGMT promoter methylation and most (71%) also had chromosome 1p/19q codeletions. Conversely, few patients with OA showed MGMT promoter methylation (23%) or had chromosome 1p/19q codeletions (31%).
Discussion
Primary treatment with temozolomide for patients with newly diagnosed OD/OA was efficacious and well tolerated in our study. The 6-month PFS rate was 77% (95% CI, 74.5% -79.3%), RR was 53%, the disease stabilization rate was 23%, median PFS was 21 months (95% CI, 3-39 months), and median OS was 43 months (95% CI, 20 -66 months). Our results are very similar to the results of other studies examining first-line temozolomide in patients with OD/OA. 4, 8, 9 The preliminary results of the NOA-04 study are of particular interest. 4 This trial randomized newly diagnosed patients with AA/OD/OA to first-line treatment with either radiotherapy or chemotherapy (temozolomide or PCV). 4 In the chemotherapy arm, the median PFS was 32 months and the median OS was not yet reached. This was equivalent to the outcomes in the standard arm with radiotherapy. Temozolomide showed equivalent tolerability to radiotherapy, but was much better tolerated than PCV. Mature results are awaited to see if these results are maintained in the subset of patients with OD/OA, although the similarity of results between the 3 studies in patients with OD/OA (our study and 2 others 8, 9 ) and the NOA-A4 study is reassuring. When available, the results of the on-going EORTC 26081 Phase III trial will also be highly relevant.
Our data also contributes to the on-going research about the use of biomarkers in these tumors. It supports previous data 9 -11,15,16 regarding the existence of specific molecular signatures in gliomas. In our study, the majority of the patients with OD have concurrent 1p/ 19q codeletions and MGMT promoter methylation, while patients with OA usually lacked both. It was not possible to examine the impact of each signature on response or survival because of limited numbers. However, we were able to examine the predictive value of concurrent 1p/19q codeletions or MGMT methylation as individual variables. Like other studies, 3, 4, 6, 7 we showed that the presence of either chromosome 1p/ 19q codeletions or MGMT promoter methylation was associated with higher RRs to chemotherapy. However, we failed to show that either had an impact on survival. This probably reflects the small sample size of our study, compounded by the inability to evaluate MGMT methylation status in about half of the patients. However, one strength of our data is the homogenous In conclusion, the data from our study and others would suggest that primary chemotherapy may be an Conflict of interest statement. LC has previously received travel assistance from Schering-Plough and served on an advisory board for Schering-Plough.
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